<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">35328090</PMID><DateCompleted><Year>2022</Year><Month>12</Month><Day>27</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>27</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2073-4425</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><Issue>3</Issue><PubDate><Year>2022</Year><Month>Mar</Month><Day>18</Day></PubDate></JournalIssue><Title>Genes</Title><ISOAbbreviation>Genes (Basel)</ISOAbbreviation></Journal><ArticleTitle><i>SOD-1</i> Variants in Amyotrophic Lateral Sclerosis: Systematic Re-Evaluation According to ACMG-AMP Guidelines.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">537</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/genes13030537</ELocationID><Abstract><AbstractText>Amyotrophic lateral sclerosis (ALS) is the most common type of motor neuron disease whose causes are unclear. The first ALS gene associated with the autosomal dominant form of the disease was <i>SOD1</i>. This gene has a high rate of rare variants, and an appropriate classification is essential for a correct ALS diagnosis. In this study, we re-evaluated the classification of all previously reported <i>SOD1</i> variants (<i>n</i> = 202) from ALSoD, project MinE, and in-house databases by applying the ACMG-AMP criteria to ALS. New bioinformatics analysis, frequency rating, and a thorough search for functional studies were performed. We also proposed adjusting criteria strength describing how to apply them to <i>SOD1</i> variants. Most of the previously reported variants have been reclassified as likely pathogenic and pathogenic based on the modified weight of the PS3 criterion, highlighting how in vivo or in vitro functional studies are determining their interpretation and classification. Furthermore, this study reveals the concordance and discordance of annotations between open databases, indicating the need for expert review to adapt the study of variants to a specific disease. Indeed, in complex diseases, such as ALS, the oligogenic inheritance, the presence of genes that act as risk factors and the reduced penetration must be considered. Overall, the diagnosis of ALS remains clinical, and improving variant classification could support genetic data as diagnostic criteria.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ruffo</LastName><ForeName>Paola</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0001-6246-5901</Identifier><AffiliationInfo><Affiliation>Medical Genetics Laboratory, Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, 87036 Rende, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Perrone</LastName><ForeName>Benedetta</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0002-9255-7492</Identifier><AffiliationInfo><Affiliation>Medical Genetics Laboratory, Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, 87036 Rende, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Conforti</LastName><ForeName>Francesca Luisa</ForeName><Initials>FL</Initials><Identifier Source="ORCID">0000-0001-8364-1783</Identifier><AffiliationInfo><Affiliation>Medical Genetics Laboratory, Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, 87036 Rende, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>03</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Genes (Basel)</MedlineTA><NlmUniqueID>101551097</NlmUniqueID><ISSNLinking>2073-4425</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000606290">SOD1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D000072105">Superoxide Dismutase-1</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019295" MajorTopicYN="N">Computational Biology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020412" MajorTopicYN="N">Multifactorial Inheritance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000072105" MajorTopicYN="Y">Superoxide Dismutase-1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ACMG-AMP guidelines</Keyword><Keyword MajorTopicYN="N">SOD1</Keyword><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">database</Keyword><Keyword MajorTopicYN="N">pathogenicity</Keyword><Keyword MajorTopicYN="N">re-evaluation</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>1</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>3</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>3</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>3</Month><Day>25</Day><Hour>1</Hour><Minute>6</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>3</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>4</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35328090</ArticleId><ArticleId IdType="pmc">PMC8955492</ArticleId><ArticleId IdType="doi">10.3390/genes13030537</ArticleId><ArticleId IdType="pii">genes13030537</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Riancho J., Delgado-Alvarado M., Andreu M.D., Paz-Fajardo L., Arozamena S., Gil-Bea F.J., de Muna&#xed;n A.L. Amyotrophic lateral sclerosis (ALS), cancer, autoimmunity and metabolic disorders: An unsolved tantalizing challenge. Br. J. Pharmacol. 2021;178:1269&#x2013;1278. doi: 10.1111/bph.15151.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bph.15151</ArticleId><ArticleId IdType="pubmed">32497246</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu L., Liu T., Liu L., Yao X., Chen L., Fan D., Zhan S., Wang S. Global variation in prevalence and incidence of amyotrophic lateral sclerosis: A systematic review and meta-analysis. J. Neurol. 2020;267:944&#x2013;953. doi: 10.1007/s00415-019-09652-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-019-09652-y</ArticleId><ArticleId IdType="pubmed">31797084</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruffo P., Strafella C., Cascella R., Caputo V., Conforti F.L., And&#xf2; S., Giardina E. Deregulation of ncRNA in Neurodegenerative Disease: Focus on circRNA, lncRNA and miRNA in Amyotrophic Lateral Sclerosis. Front. Genet. 2021;12:784996. doi: 10.3389/fgene.2021.784996.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fgene.2021.784996</ArticleId><ArticleId IdType="pmc">PMC8674781</ArticleId><ArticleId IdType="pubmed">34925464</ArticleId></ArticleIdList></Reference><Reference><Citation>Perrone B., Conforti F.L. Common mutations of interest in the diagnosis of amyotrophic lateral sclerosis: How common are common mutations in ALS genes? Expert Rev. Mol. Diagn. 2020;20:703&#x2013;714. doi: 10.1080/14737159.2020.1779060.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14737159.2020.1779060</ArticleId><ArticleId IdType="pubmed">32497448</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosen D.R., Siddique T., Patterson D., Figlewicz D.A., Sapp P., Hentati A., Donaldson D., Goto J., O&#x2019;Regan J.P., Deng H.-X., et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature. 1993;362:59&#x2013;62. doi: 10.1038/362059a0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/362059a0</ArticleId><ArticleId IdType="pubmed">8446170</ArticleId></ArticleIdList></Reference><Reference><Citation>Berdy&#x144;ski M., Miszta P., Safranow K., Andersen P.M., Morita M., Filipek S., &#x17b;ekanowski C., Ku&#x17a;ma-Kozakiewicz M. SOD1 mutations associated with amyotrophic lateral sclerosis analysis of variant severity. Sci. Rep. 2022;12:1&#x2013;11. doi: 10.1038/s41598-021-03891-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-03891-8</ArticleId><ArticleId IdType="pmc">PMC8742055</ArticleId><ArticleId IdType="pubmed">34996976</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaur S.J., McKeown S.R., Rashid S. Mutant SOD1 mediated pathogenesis of Amyotrophic Lateral Sclerosis. Gene. 2016;577:109&#x2013;118. doi: 10.1016/j.gene.2015.11.049.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.gene.2015.11.049</ArticleId><ArticleId IdType="pubmed">26657039</ArticleId></ArticleIdList></Reference><Reference><Citation>Lattante S., Marangi G., Doronzio P.N., Conte A., Bisogni G., Zollino M., Sabatelli M. High-Throughput Genetic Testing in ALS: The Challenging Path of Variant Classification Considering the ACMG Guidelines. Genes. 2020;11:1123. doi: 10.3390/genes11101123.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/genes11101123</ArticleId><ArticleId IdType="pmc">PMC7600768</ArticleId><ArticleId IdType="pubmed">32987860</ArticleId></ArticleIdList></Reference><Reference><Citation>Richards S., Aziz N., Bale S., Bick D., Das S., Gastier-Foster J., Grody W.W., Hegde M., Lyon E., Spector E., et al. Standards and guidelines for the interpretation of sequence variants: A joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet. Med. 2015;17:405&#x2013;423. doi: 10.1038/gim.2015.30.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/gim.2015.30</ArticleId><ArticleId IdType="pmc">PMC4544753</ArticleId><ArticleId IdType="pubmed">25741868</ArticleId></ArticleIdList></Reference><Reference><Citation>Abou Tayoun A.N., Pesaran T., DiStefano M.T., Oza A., Rehm H.L., Biesecker L.G., Harrison S.M., ClinGen Sequence Variant Interpretation Working Group (ClinGen SVI) Recommendations for interpreting the loss of function PVS1 ACMG/AMP variant criterion. Hum. Mutat. 2018;39:1517&#x2013;1524. doi: 10.1002/humu.23626.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/humu.23626</ArticleId><ArticleId IdType="pmc">PMC6185798</ArticleId><ArticleId IdType="pubmed">30192042</ArticleId></ArticleIdList></Reference><Reference><Citation>Biesecker L.G., Harrison S.M., e ClinGen Sequence Variant Interpretation Working Group The ACMG/AMP reputable source criteria for the interpretation of sequence variants. Genet. Med. 2018;20:1687&#x2013;1688. doi: 10.1038/gim.2018.42.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/gim.2018.42</ArticleId><ArticleId IdType="pmc">PMC6709533</ArticleId><ArticleId IdType="pubmed">29543229</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghosh R., Harrison S.M., Rehm H.L., Plon S.E., Biesecker L.G., on behalf of ClinGen Sequence Variant Interpretation Working Group Updated recommendation for the benign stand-alone ACMG/AMP criterion. Hum. Mutat. 2018;39:1525&#x2013;1530. doi: 10.1002/humu.23642.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/humu.23642</ArticleId><ArticleId IdType="pmc">PMC6188666</ArticleId><ArticleId IdType="pubmed">30311383</ArticleId></ArticleIdList></Reference><Reference><Citation>Brnich S.E., On behalf of the Clinical Genome Resource Sequence Variant Interpretation Working Group. Tayoun A.N.A., Couch F.J., Cutting G.R., Greenblatt M.S., Heinen C.D., Kanavy D.M., Luo X., McNulty S.M., et al. Recommendations for application of the functional evidence PS3/BS3 criterion using the ACMG/AMP sequence variant interpretation framework. Genome Med. 2019;12:1&#x2013;12. doi: 10.1186/s13073-019-0690-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13073-019-0690-2</ArticleId><ArticleId IdType="pmc">PMC6938631</ArticleId><ArticleId IdType="pubmed">31892348</ArticleId></ArticleIdList></Reference><Reference><Citation>Andersen P.M., Nilsson P., Forsgren L., Marklund S.L. CuZn-Superoxide Dismutase, Extracellular Superoxide Dismutase, and Glutathione Peroxidase in Blood from Individuals Homozygous for Asp90Ala CuZn-Superoxide Dismutase Mutation. J. Neurochem. 1998;70:715&#x2013;720. doi: 10.1046/j.1471-4159.1998.70020715.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1471-4159.1998.70020715.x</ArticleId><ArticleId IdType="pubmed">9453566</ArticleId></ArticleIdList></Reference><Reference><Citation>Muratet F., Teyssou E., Chiot A., Boill&#xe9;e S., Lobsiger C.S., Bohl D., Gyorgy B., Guegan J., Marie Y., Amador M.D.M., et al. Impact of a frequent nearsplice SOD1 variant in amyotrophic lateral sclerosis: Optimising SOD1 genetic screening for gene therapy opportunities. J. Neurol. Neurosurg. Psychiatry. 2021;92:942&#x2013;949. doi: 10.1136/jnnp-2020-325921.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2020-325921</ArticleId><ArticleId IdType="pubmed">33785574</ArticleId></ArticleIdList></Reference><Reference><Citation>Gentile G., Perrone B., Morello G., Simone I.L., And&#xf2; S., Cavallaro S., Conforti F.L. Individual Oligogenic Background in p.D91A-SOD1 Amyotrophic Lateral Sclerosis Patients. Genes. 2021;12:1843. doi: 10.3390/genes12121843.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/genes12121843</ArticleId><ArticleId IdType="pmc">PMC8701978</ArticleId><ArticleId IdType="pubmed">34946792</ArticleId></ArticleIdList></Reference><Reference><Citation>Hand C.K., Mayeux-Portas V., Khoris J., Briolotti V., Clavelou P., Camu W., Rouleau G.A. Compound Heterozygous D90A and D96N SOD1 Mutations in a Recessive Amyotrophic Lateral Sclerosis Family. Ann. Neurol. 2001;49:267&#x2013;271. doi: 10.1002/1531-8249(20010201)49:2&lt;267::AID-ANA51&gt;3.0.CO;2-D.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/1531-8249(20010201)49:2&lt;267::AID-ANA51&gt;3.0.CO;2-D</ArticleId><ArticleId IdType="pubmed">11220750</ArticleId></ArticleIdList></Reference><Reference><Citation>Ungaro C., Sprovieri T., Morello G., Perrone B., Spampinato A.G., Simone I.L., Trojsi F., Monsurr&#xf2; M.R., Spataro R., La Bella V., et al. Genetic investigation of amyotrophic lateral sclerosis patients in south Italy: A two-decade analysis. Neurobiol. Aging. 2021;99:99.e7&#x2013;99.e14. doi: 10.1016/j.neurobiolaging.2020.08.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2020.08.017</ArticleId><ArticleId IdType="pubmed">32951934</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks B.R., Miller R.G., Swash M., Munsat T.L., World Federation of Neurology Research Group on Motor Neuron Diseases El Escorial revisited: Revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. Other Motor Neuron Disord. 2000;1:293&#x2013;299. doi: 10.1080/146608200300079536.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/146608200300079536</ArticleId><ArticleId IdType="pubmed">11464847</ArticleId></ArticleIdList></Reference><Reference><Citation>Oza A.M., DiStefano M.T., Hemphill S.E., Cushman B.J., Grant A.R., Siegert R.K., Shen J., Chapin A., Boczek N.J., Schimmenti L.A., et al. Expert specification of the ACMG/AMP variant interpretation guidelines for genetic hearing loss. Hum. Mutat. 2018;39:1593&#x2013;1613. doi: 10.1002/humu.23630.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/humu.23630</ArticleId><ArticleId IdType="pmc">PMC6188673</ArticleId><ArticleId IdType="pubmed">30311386</ArticleId></ArticleIdList></Reference><Reference><Citation>Li J., Zhao T., Zhang Y., Zhang K., Shi L., Chen Y., Wang X., Sun Z. Performance evaluation of pathogenicity-computation methods for missense variants. Nucleic Acids Res. 2018;46:7793&#x2013;7804. doi: 10.1093/nar/gky678.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gky678</ArticleId><ArticleId IdType="pmc">PMC6125674</ArticleId><ArticleId IdType="pubmed">30060008</ArticleId></ArticleIdList></Reference><Reference><Citation>Davieson C.D., Joyce K.E., Sharma L., Shovlin C.L. DNA variant classification&#x2013;reconsidering &#x201c;allele rarity&#x201d; and &#x201c;phenotype&#x201d; criteria in ACMG/AMP guidelines. Eur. J. Med. Genet. 2021;64:104312. doi: 10.1016/j.ejmg.2021.104312.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejmg.2021.104312</ArticleId><ArticleId IdType="pubmed">34411772</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar P., Henikoff S., Ng P.C. Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. Nat. Protoc. 2009;4:1073&#x2013;1081. doi: 10.1038/nprot.2009.86.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nprot.2009.86</ArticleId><ArticleId IdType="pubmed">19561590</ArticleId></ArticleIdList></Reference><Reference><Citation>Adzhubei I.A., Schmidt S., Peshkin L., Ramensky V.E., Gerasimova A., Bork P., Kondrashov A.S., Sunyaev S.R. A method and server for predicting damaging missense mutations. Nat. Methods. 2010;7:248&#x2013;249. doi: 10.1038/nmeth0410-248.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nmeth0410-248</ArticleId><ArticleId IdType="pmc">PMC2855889</ArticleId><ArticleId IdType="pubmed">20354512</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwarz J.M., R&#xf6;delsperger C., Schuelke M., Seelow D. MutationTaster evaluates disease-causing potential of sequence alterations. Nat. Methods. 2010;7:575&#x2013;576. doi: 10.1038/nmeth0810-575.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nmeth0810-575</ArticleId><ArticleId IdType="pubmed">20676075</ArticleId></ArticleIdList></Reference><Reference><Citation>Reva B., Antipin Y., Sander C. Predicting the functional impact of protein mutations: Application to cancer genomics. Nucleic Acids Res. 2011;39:e118. doi: 10.1093/nar/gkr407.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkr407</ArticleId><ArticleId IdType="pmc">PMC3177186</ArticleId><ArticleId IdType="pubmed">21727090</ArticleId></ArticleIdList></Reference><Reference><Citation>Shihab H.A., Gough J., Cooper D.N., Day I.N.M., Gaunt T.R. Predicting the functional consequences of cancer-associated amino acid substitutions. Bioinformatics. 2013;29:1504&#x2013;1510. doi: 10.1093/bioinformatics/btt182.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btt182</ArticleId><ArticleId IdType="pmc">PMC3673218</ArticleId><ArticleId IdType="pubmed">23620363</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi Y., Sims G.E., Murphy S., Miller J.R., Chan A.P. Predicting the Functional Effect of Amino Acid Substitutions and Indels. PLoS ONE. 2012;7:e46688. doi: 10.1371/journal.pone.0046688.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0046688</ArticleId><ArticleId IdType="pmc">PMC3466303</ArticleId><ArticleId IdType="pubmed">23056405</ArticleId></ArticleIdList></Reference><Reference><Citation>Kircher M., Witten D.M., Jain P., O&#x2019;Roak B.J., Cooper G.M., Shendure J. A general framework for estimating the relative pathogenicity of human genetic variants. Nat. Genet. 2014;46:310&#x2013;315. doi: 10.1038/ng.2892.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.2892</ArticleId><ArticleId IdType="pmc">PMC3992975</ArticleId><ArticleId IdType="pubmed">24487276</ArticleId></ArticleIdList></Reference><Reference><Citation>Baux D., Van Goethem C., Ardouin O., Guignard T., Bergougnoux A., Koenig M., Roux A.-F. MobiDetails: Online DNA variants interpretation. Eur. J. Hum. Genet. 2021;29:356&#x2013;360. doi: 10.1038/s41431-020-00755-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41431-020-00755-z</ArticleId><ArticleId IdType="pmc">PMC7868358</ArticleId><ArticleId IdType="pubmed">33161418</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonifacino T., Zerbo R.A., Balbi M., Torazza C., Frumento G., Fedele E., Bonanno G., Milanese M. Nearly 30 Years of Animal Models to Study Amyotrophic Lateral Sclerosis: A Historical Overview and Future Perspectives. Int. J. Mol. Sci. 2021;22:12236. doi: 10.3390/ijms222212236.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms222212236</ArticleId><ArticleId IdType="pmc">PMC8619465</ArticleId><ArticleId IdType="pubmed">34830115</ArticleId></ArticleIdList></Reference><Reference><Citation>Myszczynska M., Ferraiuolo L. NewIn VitroModels to Study Amyotrophic Lateral Sclerosis. Brain Pathol. 2016;26:258&#x2013;265. doi: 10.1111/bpa.12353.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bpa.12353</ArticleId><ArticleId IdType="pmc">PMC8029155</ArticleId><ArticleId IdType="pubmed">26780562</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner B.J., Talbot K. Transgenics, toxicity and therapeutics in rodent models of mutant SOD1-mediated familial ALS. Prog. Neurobiol. 2008;85:94&#x2013;134. doi: 10.1016/j.pneurobio.2008.01.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pneurobio.2008.01.001</ArticleId><ArticleId IdType="pubmed">18282652</ArticleId></ArticleIdList></Reference><Reference><Citation>Ilieva H., Polymenidou M., Cleveland D.W. Non&#x2013;cell autonomous toxicity in neurodegenerative disorders: ALS and beyond. J. Cell Biol. 2009;187:761&#x2013;772. doi: 10.1083/jcb.200908164.</Citation><ArticleIdList><ArticleId IdType="doi">10.1083/jcb.200908164</ArticleId><ArticleId IdType="pmc">PMC2806318</ArticleId><ArticleId IdType="pubmed">19951898</ArticleId></ArticleIdList></Reference><Reference><Citation>Rothstein J.D. Current hypotheses for the underlying biology of amyotrophic lateral sclerosis. Ann. Neurol. 2009;65:S3&#x2013;S9. doi: 10.1002/ana.21543.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.21543</ArticleId><ArticleId IdType="pubmed">19191304</ArticleId></ArticleIdList></Reference><Reference><Citation>Guissart C., Mouzat K., Kantar J., Louveau B., Vilquin P., Polge A., Raoul C., Lumbroso S. Premature termination codons in SOD1 causing Amyotrophic Lateral Sclerosis are predicted to escape the nonsense-mediated mRNA decay. Sci. Rep. 2020;10:1&#x2013;7. doi: 10.1038/s41598-020-77716-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-020-77716-5</ArticleId><ArticleId IdType="pmc">PMC7691510</ArticleId><ArticleId IdType="pubmed">33244158</ArticleId></ArticleIdList></Reference><Reference><Citation>Fokkema I.F.A.C., Taschner P.E.M., Schaafsma G., Celli J., Laros J.F., Dunnen J.T.D. LOVD v.2.0: The next generation in gene variant databases. Hum. Mutat. 2011;32:557&#x2013;563. doi: 10.1002/humu.21438.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/humu.21438</ArticleId><ArticleId IdType="pubmed">21520333</ArticleId></ArticleIdList></Reference><Reference><Citation>Landrum M.J., Lee J.M., Benson M., Brown G.R., Chao C., Chitipiralla S., Gu B., Hart J., Hoffman D., Jang W., et al. ClinVar: Improving access to variant interpretations and supporting evidence. Nucleic Acids Res. 2018;46:D1062&#x2013;D1067. doi: 10.1093/nar/gkx1153.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkx1153</ArticleId><ArticleId IdType="pmc">PMC5753237</ArticleId><ArticleId IdType="pubmed">29165669</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagai M., Aoki M., Miyoshi I., Kato M., Pasinelli P., Kasai N., Brown R.H., Jr., Itoyama Y. Rats Expressing Human Cyto-solic Copper-Zinc Superoxide Dismutase Transgenes with Amyotrophic Lateral Sclerosis: Associated Mutations Develop Motor Neuron Disease. J. Neurosci. 2001;21:9246&#x2013;9256. doi: 10.1523/JNEUROSCI.21-23-09246.2001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.21-23-09246.2001</ArticleId><ArticleId IdType="pmc">PMC6763929</ArticleId><ArticleId IdType="pubmed">11717358</ArticleId></ArticleIdList></Reference><Reference><Citation>Li J., Song M., Moh S., Kim H., Kim D.-H. Cytoplasmic Restriction of Mutated SOD1 Impairs the DNA Repair Process in Spinal Cord Neurons. Cells. 2019;8:1502. doi: 10.3390/cells8121502.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells8121502</ArticleId><ArticleId IdType="pmc">PMC6952796</ArticleId><ArticleId IdType="pubmed">31771229</ArticleId></ArticleIdList></Reference><Reference><Citation>Liguori F., Amadio S., Volont&#xe9; C. Where and Why Modeling Amyotrophic Lateral Sclerosis. Int. J. Mol. Sci. 2021;22:3977. doi: 10.3390/ijms22083977.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22083977</ArticleId><ArticleId IdType="pmc">PMC8070525</ArticleId><ArticleId IdType="pubmed">33921446</ArticleId></ArticleIdList></Reference><Reference><Citation>Sasaki S., Nagai M., Aoki M., Komori T., Itoyama Y., Iwata M. Motor Neuron Disease in Transgenic Mice with an H46R Mutant SOD1 Gene. J. Neuropathol. Exp. Neurol. 2007;66:517&#x2013;524. doi: 10.1097/01.jnen.0000263868.84188.3b.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.jnen.0000263868.84188.3b</ArticleId><ArticleId IdType="pubmed">17549011</ArticleId></ArticleIdList></Reference><Reference><Citation>Jonsson P.A., Graffmo K.S., Br&#xe4;nnstr&#xf6;m T., Nilsson P., Andersen P.M., Marklund S.L. Motor Neuron Disease in Mice Expressing the Wild Type-Like D90A Mutant Superoxide Dismutase-1. J. Neuropathol. Exp. Neurol. 2006;65:1126&#x2013;1136. doi: 10.1097/01.jnen.0000248545.36046.3c.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.jnen.0000248545.36046.3c</ArticleId><ArticleId IdType="pubmed">17146286</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu H.-N., Tjostheim S., DaSilva K., Taylor D., Zhao B., Rakhit R., Brown M., Chakrabartty A., McLaurin J., Robertson J. Targeting of Monomer/Misfolded SOD1 as a Therapeutic Strategy for Amyotrophic Lateral Sclerosis. J. Neurosci. 2012;32:8791&#x2013;8799. doi: 10.1523/JNEUROSCI.5053-11.2012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.5053-11.2012</ArticleId><ArticleId IdType="pmc">PMC6622344</ArticleId><ArticleId IdType="pubmed">22745481</ArticleId></ArticleIdList></Reference><Reference><Citation>Baskoylu S.N., Yersak J., O&#x2019;Hern P., Grosser S., Simon J., Kim S., Schuch K., Dimitriadi M., Yanagi K.S., Lins J., et al. Single copy/knock-in models of ALS SOD1 in C. elegans suggest loss and gain of function have different contributions to cholinergic and glutamatergic neurodegeneration. PLoS Genet. 2018;14:e1007682. doi: 10.1371/journal.pgen.1007682.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pgen.1007682</ArticleId><ArticleId IdType="pmc">PMC6200258</ArticleId><ArticleId IdType="pubmed">30296255</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruijn L.I., Becher M.W., Lee M.K., Anderson K.L., Jenkins N.A., Copeland N.G., Sisodia S.S., Rothstein J.D., Borchelt D.R., Price D.L., et al. ALS-Linked SOD1 Mutant G85R Mediates Damage to Astrocytes and Promotes Rapidly Progressive Disease with SOD1-Containing Inclusions. Neuron. 1997;18:327&#x2013;338. doi: 10.1016/S0896-6273(00)80272-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0896-6273(00)80272-X</ArticleId><ArticleId IdType="pubmed">9052802</ArticleId></ArticleIdList></Reference><Reference><Citation>&#x15e;ahin A., Held A., Bredvik K., Major P., Achilli T.-M., Kerson A.G., Wharton K., Stilwell G., Reenan R. Human SOD1 ALS Mutations in a Drosophila Knock-In Model Cause Severe Phenotypes and Reveal Dosage-Sensitive Gain- and Loss-of-Function Components. Genetics. 2017;205:707&#x2013;723. doi: 10.1534/genetics.116.190850.</Citation><ArticleIdList><ArticleId IdType="doi">10.1534/genetics.116.190850</ArticleId><ArticleId IdType="pmc">PMC5289846</ArticleId><ArticleId IdType="pubmed">27974499</ArticleId></ArticleIdList></Reference><Reference><Citation>Witan H., Gorlovoy P., Kaya A.M., Koziollek-Drechsler I., Neumann H., Behl C., Clement A.M. Wild-type Cu/Zn superoxide dismutase (SOD1) does not facilitate, but impedes the formation of protein aggregates of amyotrophic lateral sclerosis causing mutant SOD1. Neurobiol. Dis. 2009;36:331&#x2013;342. doi: 10.1016/j.nbd.2009.07.024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2009.07.024</ArticleId><ArticleId IdType="pubmed">19660548</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramesh T., Lyon A.N., Pineda R.H., Wang C., Janssen P.M.L., Canan B.D., Burghes A., Beattie C.E. A genetic model of amyotrophic lateral sclerosis in zebrafish displays phenotypic hallmarks of motoneuron disease. Dis. Model. Mech. 2010;3:652&#x2013;662. doi: 10.1242/dmm.005538.</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/dmm.005538</ArticleId><ArticleId IdType="pmc">PMC2931540</ArticleId><ArticleId IdType="pubmed">20504969</ArticleId></ArticleIdList></Reference><Reference><Citation>Keskin I., Forsgren E., Lange D.J., Weber M., Birve A., Synofzik M., Gilthorpe J.D., Andersen P.M., Marklund S.L. Effects of Cellular Pathway Disturbances on Misfolded Superoxide Dismutase-1 in Fibroblasts Derived from ALS Patients. PLoS ONE. 2016;11:e0150133. doi: 10.1371/journal.pone.0150133.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0150133</ArticleId><ArticleId IdType="pmc">PMC4769150</ArticleId><ArticleId IdType="pubmed">26919046</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin H.-X., Tao Q.-Q., Wei Q., Chen C.-X., Chen Y.-C., Li H.-F., Gitler A.D., Wu Z.-Y. Identification and functional analysis of novel mutations in the SOD1 gene in Chinese patients with amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. Front. Degener. 2019;20:222&#x2013;228. doi: 10.1080/21678421.2019.1582668.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2019.1582668</ArticleId><ArticleId IdType="pubmed">30887850</ArticleId></ArticleIdList></Reference><Reference><Citation>Prudencio M., Hart P.J., Borchelt D.R., Andersen P.M. Variation in aggregation propensities among ALS-associated variants of SOD1: Correlation to human disease. Hum. Mol. Genet. 2009;18:3217&#x2013;3226. doi: 10.1093/hmg/ddp260.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddp260</ArticleId><ArticleId IdType="pmc">PMC2722984</ArticleId><ArticleId IdType="pubmed">19483195</ArticleId></ArticleIdList></Reference><Reference><Citation>Cozzolino M., Amori I., Pesaresi M.G., Ferri A., Nencini M., Carr&#xec; M.T. Cysteine 111 Affects Aggregation and Cytotoxicity of Mutant Cu,Zn-superoxide Dismutase Associated with Familial Amyotrophic Lateral Sclerosis. J. Biol. Chem. 2008;283:866&#x2013;874. doi: 10.1074/jbc.M705657200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M705657200</ArticleId><ArticleId IdType="pmc">PMC2842925</ArticleId><ArticleId IdType="pubmed">18006498</ArticleId></ArticleIdList></Reference><Reference><Citation>Walczak J., D&#x119;bska-Vielhaber G., Vielhaber S., Szyma&#x144;ski J., Charzy&#x144;ska A., Duszy&#x144;ski J., Szczepanowska J. Distinction of sporadic and familial forms of ALS based on mitochondrial characteristics. FASEB J. 2019;33:4388&#x2013;4403. doi: 10.1096/fj.201801843R.</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.201801843R</ArticleId><ArticleId IdType="pubmed">30550341</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L., Gutmann D.H., Roos R.P. Astrocyte loss of mutant SOD1 delays ALS disease onset and progression in G85R transgenic mice. Hum. Mol. Genet. 2011;20:286&#x2013;293. doi: 10.1093/hmg/ddq463.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddq463</ArticleId><ArticleId IdType="pubmed">20962037</ArticleId></ArticleIdList></Reference><Reference><Citation>Philips T., Rothstein J.D. Rodent Models of Amyotrophic Lateral Sclerosis. Curr. Protoc. Pharmacol. 2015;69:5.67.1&#x2013;5.67.21. doi: 10.1002/0471141755.ph0567s69.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/0471141755.ph0567s69</ArticleId><ArticleId IdType="pmc">PMC4562058</ArticleId><ArticleId IdType="pubmed">26344214</ArticleId></ArticleIdList></Reference><Reference><Citation>Allen S.P., Rajan S., Duffy L., Mortiboys H., Higginbottom A., Grierson A., Shaw P.J. Superoxide dismutase 1 mutation in a cellular model of amyotrophic lateral sclerosis shifts energy generation from oxidative phosphorylation to glycolysis. Neurobiol. Aging. 2014;35:1499&#x2013;1509. doi: 10.1016/j.neurobiolaging.2013.11.025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2013.11.025</ArticleId><ArticleId IdType="pubmed">24439480</ArticleId></ArticleIdList></Reference><Reference><Citation>Furukawa Y., Kaneko K., Yamanaka K., O&#x2019;Halloran T.V., Nukina N. Complete Loss of Post-translational Modifications Triggers Fibrillar Aggregation of SOD1 in the Familial Form of Amyotrophic Lateral Sclerosis. J. Biol. Chem. 2008;283:24167&#x2013;24176. doi: 10.1074/jbc.M802083200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M802083200</ArticleId><ArticleId IdType="pmc">PMC3259764</ArticleId><ArticleId IdType="pubmed">18552350</ArticleId></ArticleIdList></Reference><Reference><Citation>Salehi M., Nikkhah M., Ghasemi A., Arab S.S. Mitochondrial membrane disruption by aggregation products of ALS-causing superoxide dismutase-1 mutants. Int. J. Biol. Macromol. 2015;75:290&#x2013;297. doi: 10.1016/j.ijbiomac.2015.01.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijbiomac.2015.01.022</ArticleId><ArticleId IdType="pubmed">25600987</ArticleId></ArticleIdList></Reference><Reference><Citation>McAlary L., Yerbury J., Aquilina J.A. Glutathionylation potentiates benign superoxide dismutase 1 variants to the toxic forms associated with amyotrophic lateral sclerosis. Sci. Rep. 2013;3:3275. doi: 10.1038/srep03275.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep03275</ArticleId><ArticleId IdType="pmc">PMC3834562</ArticleId><ArticleId IdType="pubmed">24253732</ArticleId></ArticleIdList></Reference><Reference><Citation>McAlary L., Aquilina J.A., Yerbury J.J. Susceptibility of Mutant SOD1 to Form a Destabilized Monomer Predicts Cellular Aggregation and Toxicity but Not In vitro Aggregation Propensity. Front. Neurosci. 2016;10:499. doi: 10.3389/fnins.2016.00499.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2016.00499</ArticleId><ArticleId IdType="pmc">PMC5095133</ArticleId><ArticleId IdType="pubmed">27867347</ArticleId></ArticleIdList></Reference><Reference><Citation>Rajpurohit C.S., Kumar V., Cheffer A., Oliveira D., Ulrich H., Okamoto O.K., Zatz M., Ansari U.A., Khanna V.K., Pant A.B. Mechanistic Insights of Astrocyte-Mediated Hyperactive Autophagy and Loss of Motor Neuron Function in SOD1L39R Linked Amyotrophic Lateral Sclerosis. Mol. Neurobiol. 2020;57:4117&#x2013;4133. doi: 10.1007/s12035-020-02006-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-020-02006-0</ArticleId><ArticleId IdType="pubmed">32676988</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhong Y., Wang J., Henderson M., Yang P., Hagen B.M., Siddique T., E Vogel B., Deng H.-X., Fang S. Nuclear export of misfolded SOD1 mediated by a normally buried NES-like sequence reduces proteotoxicity in the nucleus. eLife. 2017;6:e23759. doi: 10.7554/eLife.23759.</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.23759</ArticleId><ArticleId IdType="pmc">PMC5449186</ArticleId><ArticleId IdType="pubmed">28463106</ArticleId></ArticleIdList></Reference><Reference><Citation>Amendola L.M., Jarvik G.P., Leo M.C., McLaughlin H.M., Akkari Y., Amaral M.D., Berg J.S., Biswas S., Bowling K.M., Conlin L.K., et al. Performance of ACMG-AMP Variant-Interpretation Guidelines among Nine Laboratories in the Clinical Sequencing Exploratory Research Consortium. Am. J. Hum. Genet. 2016;99:247. doi: 10.1016/j.ajhg.2016.06.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajhg.2016.06.001</ArticleId><ArticleId IdType="pmc">PMC5005465</ArticleId><ArticleId IdType="pubmed">27392081</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Chalabi A., Hardiman O. The epidemiology of ALS: A conspiracy of genes, environment and time. Nat. Rev. Neurol. 2013;9:617&#x2013;628. doi: 10.1038/nrneurol.2013.203.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2013.203</ArticleId><ArticleId IdType="pubmed">24126629</ArticleId></ArticleIdList></Reference><Reference><Citation>Bozzoni V., Pansarasa O., Diamanti L., Nosari G., Cereda C., Ceroni M. Amyotrophic lateral sclerosis and environmental factors. Funct. Neurol. 2016;31:7&#x2013;19. doi: 10.11138/FNeur/2016.31.1.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.11138/FNeur/2016.31.1.007</ArticleId><ArticleId IdType="pmc">PMC4819821</ArticleId><ArticleId IdType="pubmed">27027889</ArticleId></ArticleIdList></Reference><Reference><Citation>Highley J., Pons A.L., Cooper-Knock J., Wharton S.B., Ince P., Shaw P., Wood J., Kirby J. Motor neurone disease/amyotrophic lateral sclerosis associated with intermediate length CAG repeat expansions in Ataxin-2 does not have 1C2-positive polyglutamine inclusions. Neuropathol. Appl. Neurobiol. 2015;42:377&#x2013;389. doi: 10.1111/nan.12254.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/nan.12254</ArticleId><ArticleId IdType="pubmed">26095883</ArticleId></ArticleIdList></Reference><Reference><Citation>Yousefian-Jazi A., Sung M.K., Lee T., Hong Y.-H., Choi J.K., Choi J. Functional fine-mapping of noncoding risk variants in amyotrophic lateral sclerosis utilizing convolutional neural network. Sci. Rep. 2020;10:1&#x2013;12. doi: 10.1038/s41598-020-69790-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-020-69790-6</ArticleId><ArticleId IdType="pmc">PMC7393092</ArticleId><ArticleId IdType="pubmed">32732921</ArticleId></ArticleIdList></Reference><Reference><Citation>Scarlino S., Domi T., Pozzi L., Romano A., Pipitone G.B., Falzone Y.M., Mosca L., Penco S., Lunetta C., Sansone V., et al. Burden of Rare Variants in ALS and Axonal Hereditary Neuropathy Genes Influence Survival in ALS: Insights from a Next Generation Sequencing Study of an Italian ALS Cohort. Int. J. Mol. Sci. 2020;21:3346. doi: 10.3390/ijms21093346.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms21093346</ArticleId><ArticleId IdType="pmc">PMC7246633</ArticleId><ArticleId IdType="pubmed">32397312</ArticleId></ArticleIdList></Reference><Reference><Citation>Shibata N., Asayama K., Hirano A., Kobayashi M. Immunohistochemical Study on Superoxide Dismutases in Spinal Cords from Autopsied Patients with Amyotrophic Lateral Sclerosis. Dev. Neurosci. 1996;18:492&#x2013;498. doi: 10.1159/000111445.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000111445</ArticleId><ArticleId IdType="pubmed">8940623</ArticleId></ArticleIdList></Reference><Reference><Citation>Gruzman A., Wood W.L., Alpert E., Prasad M.D., Miller R.G., Rothstein J.D., Bowser R., Hamilton R., Wood T.D., Cleveland D.W., et al. Common molecular signature in SOD1 for both sporadic and familial amyotrophic lateral sclerosis. Proc. Natl. Acad. Sci. USA. 2007;104:12524&#x2013;12529. doi: 10.1073/pnas.0705044104.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0705044104</ArticleId><ArticleId IdType="pmc">PMC1941502</ArticleId><ArticleId IdType="pubmed">17636119</ArticleId></ArticleIdList></Reference><Reference><Citation>Denham N.C., Pearman C.M., Ding W.Y., Waktare J., Gupta D., Snowdon R., Hall M., Cooper R., Modi S., Todd D., et al. Systematic re-evaluation of SCN5A variants associated with Brugada syndrome. J. Cardiovasc. Electrophysiol. 2018;30:118&#x2013;127. doi: 10.1111/jce.13740.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jce.13740</ArticleId><ArticleId IdType="pubmed">30203441</ArticleId></ArticleIdList></Reference><Reference><Citation>Sau D., De Biasi S., Vitellaro-Zuccarello L., Riso P., Guarnieri S., Porrini M., Simeoni S., Crippa V., Onesto E., Palazzolo I., et al. Mutation of SOD1 in ALS: A gain of a loss of function. Hum. Mol. Genet. 2007;16:1604&#x2013;1618. doi: 10.1093/hmg/ddm110.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddm110</ArticleId><ArticleId IdType="pubmed">17504823</ArticleId></ArticleIdList></Reference><Reference><Citation>Saccon R.A., Bunton-Stasyshyn R.K.A., Fisher E.M., Fratta P. Is SOD1 loss of function involved in amyotrophic lateral sclerosis? Brain. 2013;136:2342&#x2013;2358. doi: 10.1093/brain/awt097.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awt097</ArticleId><ArticleId IdType="pmc">PMC3722346</ArticleId><ArticleId IdType="pubmed">23687121</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>